Quantitative PCR (qPCR), also known as Real-Time PCR, is the industry-standard method for detection and quantification of nucleic acids. While newer technologies like Digital PCR (dPCR) are gaining traction for viral titering, qPCR remains a widely accepted GMP method for impurity testing - particularly for Residual Host Cell DNA (resDNA) - and is commonly used for rapid mycoplasma detection; NAT-based mycoplasma methods are accepted per USP <63> and Ph. Eur. 2.6.7

In practice, qPCR answers the question “Is unwanted DNA present, and how much?” rather than “How many viral genomes are present?”

Legacy Techniques: End-point PCR (Gel Electrophoresis). This method was qualitative (Yes/No).

Established: qPCR (Real-Time PCR). By measuring fluorescence accumulation during the reaction, qPCR enables precise quantification relative to a standard curve. It is the current workhorse for safety and impurity assays.

Emerging Alternative: Digital PCR (dPCR). dPCR is replacing qPCR for applications requiring absolute quantification (like AAV Viral Titer) because it does not rely on a reference standard. However, qPCR retains its dominance in high-volume screening and impurity testing where broad dynamic range is more important than absolute precision.

qPCR monitors the amplification of a target DNA sequence in real-time using fluorescent reporters.

Amplification: The sample undergoes thermal cycling (Denaturation, Annealing, Extension).

Detection:

TaqMan (Hydrolysis Probes): A fluorophore-labeled probe binds specifically to the target sequence. As the polymerase extends the new DNA strand, it cleaves the probe, releasing the fluorophore to emit light. This is the preferred chemistry for GMP assays due to its high specificity.

Quantification (Ct Value): The instrument calculates the Cycle Threshold (Ct), the cycle number at which the fluorescence signal crosses a defined background threshold.

Low Ct: High concentration of target DNA (signal detected early).

High Ct: Low concentration of target DNA (signal detected late).

Output: The primary readout is the Amplification Plot (Delta Rn vs. Cycle) and the Standard Curve (Ct vs. Log Quantity).

Analysis:

Efficiency: Calculated from the slope of the standard curve (Ideal slope = -3.32, representing 100% efficiency).

Linearity (R^2): Measures how well the standard curve fits the data. GMP assays typically require R^2 ≥ 0.98.

Interpretation:

For Residual DNA, the sample Ct is interpolated against the standard curve to calculate concentration (e.g., ng/mL).

For Mycoplasma, a result is "Positive" if the Ct is below the validated limit of detection (LOD) and the internal control is valid.

Wide Dynamic Range: Capable of quantifying targets over 7 to 8 orders of magnitude (Logs). This is critical for residual DNA, which can vary wildly between purification steps.

High Throughput: 384-well plate compatibility allows for the testing of hundreds of samples in a single run.

Cost-Effective: Significantly lower cost-per-sample compared to dPCR or NGS.

Speed: Fast cycling protocols can deliver results in <60 minutes.

Reference Standard Dependency: Accuracy is entirely dependent on the standard curve. If the reference standard is inaccurate or degrades, the sample result will be biased.

Inhibitor Sensitivity: Complex sample matrices (containing salts, detergents, or media) can inhibit the polymerase, shifting Ct values. (dPCR is generally more robust to inhibitors).

Relative Quantification: It does not count molecules directly; it estimates them based on amplification kinetics.

Comparison: qPCR vs. Digital PCR (dPCR)

Limit of Quantitation (LOQ): Crucial for impurity assays. You must prove the method can precisely quantify DNA at the regulatory limit ≤10 ng per dose (per WHO/FDA guidance, product- and modality-specific).

Specificity: Validation must demonstrate that primers do not cross-react with non-target DNA (e.g., ensuring CHO-specific primers do not cross-react with human genomic DNA).

Accuracy (Spike Recovery): Spiking a known amount of standard into the sample matrix to verify that the matrix does not inhibit the reaction (Acceptance criteria often 70–130%).

MIQE Guidelines: The industry standard for reporting is the MIQE (Minimum Information for Publication of Quantitative Real-Time PCR Experiments) guidelines. These require reporting of specific details (primer sequences, efficiency, R^2) to ensure assay reproducibility.

Reference Materials: Certified Reference Materials (CRMs): For absolute quantification, assays should ideally be calibrated against NIST SRM materials for human DNA quantitation (e.g., well-characterized genomic DNA standards), or WHO International Standards for viral targets.

Internal Reference Standard: For impurity assays (e.g., CHO Host Cell DNA), a "Master Standard" derived from the specific cell line used in production is created, characterized, and used to generate the standard curve for every plate.

Normalization: For gene expression assays, results must be normalized against validated Reference Genes (housekeeping genes like GAPDH, ACTB, or 18S rRNA) that are stably expressed under the experimental conditions.

mRNA Vaccines & Therapeutics:

Residual Plasmid DNA: The primary release test. qPCR targets the non-coding regions of the DNA template (e.g., the Kanamycin resistance gene or Origin of Replication) to quantify residual plasmid that was not digested by DNase I.

Gene Therapy (AAV/Lenti):

Replication Competent Virus (RCL for lentivirus, RCA for AAV/adenovirus): A critical safety assay used to detect if the viral vector has recombined to become replication-competent.

Mycoplasma: Used for rapid release of bulk harvest (substituting the 28-day culture method).

Genome Titering (Screening): Used for in-process high-throughput screening of Vector Genome (VG) titer during upstream process development (DoE), before final confirmation by dPCR.

Viral Clearance Studies: During downstream validation, qPCR is used to measure the "Log Reduction Value" (LRV) of spiked model viruses (e.g., MVM, X-MuLV) across chromatography and filtration steps.

Residual Host Cell DNA: Routine lot release testing to confirm DNA clearance to <10 ng/dose per WHO guidelines; may vary by modality and regulatory region.